Loteprednol etabonate 0.2%

DRUG2 trials

Sponsors

ORA, Inc., Bausch & Lomb Incorporated

Conditions

Allergic ConjunctivitisSeasonal Allergic Conjunctivitis

Phase 3

Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

CompletedNCT01435460

Bausch & Lomb IncorporatedSeasonal Allergic Conjunctivitis

Start: 2010-08-31End: 2011-05-31Updated: 2012-03-13

Phase 4

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

CompletedNCT00689078

ORA, Inc.Allergic Conjunctivitis

Start: 2008-05-31End: 2008-06-30Updated: 2020-09-02

Related Papers

Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.

2012-05-2317 citations